SAN DIEGO - Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today highlights new preclinical data supporting the potential of its fully non-viral lead genetic medicines programs and related platform technologies.

The data was included in three oral and three poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting, being held in Baltimore, MD and virtually on May 7-11, 2024.

'Poseida's unique and proprietary toolkit, which enables non-viral gene insertion, high-fidelity gene editing, and associated delivery and manufacturing technologies, has been the driving force behind our emerging genetic medicines programs and our clinical stage allogeneic CAR-T pipeline,' said Blair Madison, Ph.D., Chief Scientific Officer, Gene Therapy at Poseida Therapeutics. 'Starting with our recent R&D Day, and continuing with ASGCT, we have showcased the maturity and power of our tools specific to enabling a fully non-viral and potentially tunable approach to in vivo genetic medicine. We believe this could provide our medicines with a superior profile featuring a minimized risk of off-target effects that can be customized to each patient, when appropriate. Taken together, these data give us confidence as we continue to validate our non-viral approach, seeking to achieve durable correction in patients suffering from rare diseases such as Hereditary Angioedema and Hemophilia A.'

Oral Presentations

Title: Highly Specific Non-Viral Gene Editing with P-KLKB1-101 for Hereditary Angioedema

Presenting Author: Blair Madison, Ph.D., Poseida Therapeutics, Inc.

Session Title: Correction of Genetic Disorders of the Blood and Immune System

Presentation Date/Time: Thursday, May 9, 2024, 1:30 - 1:45 PM ET

Location: Room 314-317

Abstract Number: 170

Hereditary Angioedema (HAE) is a rare inherited disorder characterized by recurrent episodes of fluid accumulation outside of blood vessels, causing rapid swelling of tissues. HAE patients have significant unmet need for a durable, effective, and convenient treatment option that eliminates recurrent attacks. P-KLKB1-101 is a fully non-viral investigational gene editing therapy designed to enable high fidelity editing at pre-kallikrein, or KLKB1, for targeted correction of HAE. It utilizes the Cas-CLOVER nuclease to achieve clean site-specific gene editing that is engineered for high specificity. In pre-clinical studies, P-KLKB1-101 demonstrates excellent efficiency editing liver cells with off-target edits

(C) 2024 Electronic News Publishing, source ENP Newswire